Good
Mostly Aligned
Patient Risk:
Low
Summary
The evaluated label-relevant claim about severe acute exacerbations of hepatitis B after VEMLIDY discontinuation and the need for close clinical/laboratory monitoring for at least several months is supported by the provided label sections (5.1, 17, and Patient Information). However, the overall prompt includes multiple other claims not evaluated against the label text provided, reducing comprehensive alignment.
Category Scores
Accurate Statements
After discontinuing VEMLIDY for hepatitis B, patients may experience a severe acute exacerbation (HBV flare).
Supported by Section 5.1 and reiterated in Section 17 and Patient Information (worsening/flare-up if stopped).
Patients should be closely monitored with both clinical and laboratory follow-up for at least several months after stopping VEMLIDY.
Supported by Section 5.1 and Patient Information (“check your health often and do blood tests regularly for several months”).
Resumption of anti-hepatitis B therapy may be warranted if VEMLIDY is discontinued.
Supported by Section 5.1 (resumption may be warranted).
Unsupported Statements
All other claims in the provided list (e.g., pediatric use, mechanism, kidney/bone risk, interaction types, nausea/headache/fatigue, and monitoring decision points) are not evaluated against label text in the material supplied for this audit.
Only the discontinuation severe acute exacerbation/monitoring-related label sections were provided for evaluation; no label excerpts supporting or refuting the other claims were supplied.
Contradictions
Important Omissions
The AI response did not assess whether the additional listed claims (e.g., interactions with other antivirals and kidney-influencing drugs; common side effects; key decision points based on kidney function/concurrent medications/liver conditions) are supported or contradicted by the provided label excerpts.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The only directly label-evaluated safety message (HBV flare risk after discontinuation and required monitoring for several months) is consistent with the provided FDA label excerpts.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Incomplete audit coverage: many other listed claims were not verified against the provided label text.
Suggested Improvement
Restrict evaluation to claims directly tied to the supplied label excerpts, or provide the specific label sections (indications, warnings/precautions, drug interactions, adverse reactions, and counseling/monitoring details) for each additional claim.